Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro

被引：0
作者：
Multi-Imaging Centre, Department of Physiology, Development and Neuroscience, University of Cambridge, Downing Street, Cambridge, CB2 3DY, United Kingdom [1 ]
不详 [2 ]
不详 [3 ]
不详 [4 ]
不详 [5 ]
不详 [6 ]
机构：
[1] Multi-Imaging Centre, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, CB2 3DY, Downing Street
[2] Department of Earth and Environmental Sciences, Pannon University, Veszprém, H-8200
[3] Department of Radiology, University of Cambridge, Addenbrooke's Hospital, Cambridge
[4] Direction Recherche, Guerbet, 95943 Roissy CDG Cedex
[5] Neurology Biomarkers, Translational Medicine and Genetics, GlaxoSmithKline, Cambridge
[6] Clinical Imaging Applications, Translational Medicine and Genetics, GlaxoSmithKline, Greenford
来源：
Biomaterials | 2007年 / 9卷 / 1629-1642期
基金：
英国惠康基金;
关键词：
Cell activation; Cytotoxicity; Electron microscopy; Inflammation; Macrophage; Nanoparticle;
D O I：
10.1016/j.biomaterials.2006.12.003
中图分类号：
学科分类号：
摘要：
Ferumoxtran-10, a dextran-coated ultrasmall superparamagnetic iron oxide particle, has the potential to reveal macrophages in vivo using magnetic resonance imaging potentially acting as a marker of inflammatory status. Pending clinical trials, we examined the interactions of Ferumoxtran-10 with human monocyte-macrophages (HMMs) in vitro to assess its safety and lack of pro-inflammatory activity. After 72 h, Ferumoxtran-10 was not toxic at 1 mg/ml and may be only mildly toxic at 10 mg/ml. Viability in cells with a high intracellular Ferumoxtran-10 load was not affected over 14 days. Ferumoxtran-10 did not interfere with baseline or stimulated cytokine (interleukin-12, interleukin-6, tumour necrosis factor-α or interleukin-1β) or superoxide anion production or with Fc-receptor-mediated phagocytosis. Similarly, Ferumoxtran-10 did not induce cytokine production and was not chemotactic. High-resolution electron microscopy and selected-area electron diffraction confirmed the core of Ferumoxtran-10 is composed of crystalline magnetite. Bright field transmission electron microscopy of thin sections demonstrated that Ferumoxtran-10 was retained in lysosomes of HMM for several days. Ferumoxtran-10 is not toxic to HMMs in vitro, does not activate them to produce pro-inflammatory cytokines or superoxide anions, is not chemotactic and does not interfere with Fc-receptor-mediated phagocytosis. Furthermore, extremely high intracellular Ferumoxtran-10 concentrations had only slight or no effects on these key activities. © 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1629 / 1642
页数：13
相关论文
共 32 条
  • [1] Anzai Y., Prince M.R., Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer, J Magn Reson Imag, 7, pp. 75-81, (1997)
  • [2] Corot C., Petry K.G., Trivedi R., Saleh A., Jonkmanns C., Le Bas J.F., Et al., Macrophage imaging in the central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging, Invest Radiol, 39, pp. 619-625, (2004)
  • [3] Hinds K.A., Hill J.M., Shapiro E.M., Laukkanen M.O., Silva A.C., Combs C.A., Et al., Highly efficient endosomal labelling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells, Blood, 102, pp. 867-872, (2003)
  • [4] Weissleder R., Stark D.D., Engelstad B.L., Bacon B.R., Compton C.C., White D.L., Et al., Superparamagnetic iron oxide: pharmacokinetics and toxicity, Am J Radiol, 152, pp. 167-173, (1989)
  • [5] Weissleder R., Elizondo G., Wittenberg J., Rabito C.A., Bengele H.H., Josephson L., Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging, Radiology, 175, pp. 489-493, (1990)
  • [6] Wilhelm C., Billotey C., Roger J., Pons J.N., Bacri J.-C., Gazeau F., Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating, Biomaterials, 24, pp. 1001-1011, (2003)
  • [7] Metz S., Bonaterra G., Rudelius M., Settles M., Rummeny E.J., Daldrup-Link H.E., Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro, Eur Radiol, 14, pp. 1851-1858, (2004)
  • [8] Bourrinet P., Bengele H.H., Bonnemain B., Dencausse A., Idee J.M., Jacobs P.M., Et al., Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent, Invest Radiol, 41, pp. 313-324, (2006)
  • [9] Zhang Y., Dodd S.J., Hendrich K.S., Williams M., Ho C., Magnetic resonance imaging detection of rat renal transplant rejection by monitoring macrophage infiltration, Kidney Int, 58, pp. 1300-1310, (2000)
  • [10] Trivedi R.A., U-King-Im J.-M., Graves M.J., Cross J.J., Horsley J., Goddard M.J., Et al., In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI, Stroke, 35, pp. 1631-1635, (2004)
1234